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Abstract
In the era of new Hepatitis C Virus (HCV) therapy, and the detection of 
extrahepatic HCV reservoirs such as peripheral blood mononuclear 
cells and platelets, it is important to understand the factors underlying 
resistance to treatment. Detection and quantitation of HCV-RNA 
in platelets or leucocytes from patients under antiviral therapy is 
poorly studied and the limited studies generated contradictory 
results. 
Aim: To detect and quantify HCV-RNA in platelets, and to evaluate 
the relation between HCV-RNA in the serum and the kinetics of 
HCV-RNA in platelets, in response to treatment. 
Method: Viral kinetic was tested in 20 chronic HCV genotype4, 
during the course of therapy. 
Results: HCV-RNA was detected in sera of all infected patients. 
The baseline platelet viral load was significantly lower in responders 
compared to non-responders. Platelet viral load was also related to 
serum viral load (t=3.39, p=0.001), but not related to platelet count 
(t=-0.56, p=0.58). ROC curve analysis revealed that in general, 
platelet viral load at different time points was a better predictor of 
SVR compared to serum viral load.
Conclusion: HCV RNA analysis in whole blood may be more 
sensitive than platelet-poor plasma, which might underestimate 
circulating viral load. Early eradication of viremia from platelets is 
associated with higher rates of SVR. Our data, reconfirm higher 
HCV-RNA levels in serum compared to platelets. Thrombocytopenia 
occurring during interferon-based therapy might be a manifestation 
of viral eradication rather than adverse effects. Our findings warrant 
testing the sensitivity of platelet viral load as a predictor of poor 
response.
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Background
Hepatitis C virus (HCV) is one of the most important causes 
of chronic hepatitis around the globe, particularly in Egypt, where 
genotype 4 (G4) is the predominant one, and it has been detected 
at extrahepatic sites [1]. Although HCV has hepatic tropism, 
viral RNA was found in extrahepatic compartments. A few recent 
studies have demonstrated that in individuals infected with HCV, 
viral RNA is associated with platelets which act as carriers of 
the virus in the circulation leading to persistence of the virus. 
Consequently, platelet- associated viral particles would exert a 
limiting effect on the efficiency of antiviral therapy. Cytopenias 
associated with HCV infection is another limiting factor by 
delaying or may be interrupting the course of treatment [2], 
and directly interact with platelets and platelet dysfunction and 
thrombocytopenia [3]. 
HCV- associated thrombocytopenia is complex and multifactorial 
in origin. Interaction of platelets with HCV is presumed to be one 
of the pathogenic mechanisms implicated in HCV-associated 
thrombocytopenia. Also, autoimmune thrombocytopenia in chronic 
HCV infection and detection of anti-platelet antibodies, have been 
reported [4]. Specific glycoprotein antibodies [5], and immune 
complex bound to the platelet, have been reported [6]. Furthermore, 
the finding that thrombocytopenia is reversed by a selective thrombin 
receptor agonist, indicates that HCV-induced thrombocytopenia 
might be related to platelet activation due to the infection related 
inflammation [7]. Paradoxically, thrombocytopenia is not usually 
associated with bleeding tendency during treatment of hepatitis C 
with interferon and ribavirin [8]. 
The recently approved targeted therapy with Direct Acting 
Antiviral (DAAs), changed the treatment paradigm and raised the 
hope of better treatment, it offers a new era of high safety and efficacy 
to a variety of patients suffering from chronic HCV infection [9]. 
However, the current treatment course still involves the drugs, 
pegylated interferon and ribavirin (PEG-IFN/RBV) in certain 
regimens. Also, at these expensive prices, these treatments will 
remain unaffordable for most patients who need treatment. So, 
PEG-IFN- based therapy will remain for sometimes in low-income 
settings. Both HCV infection and its treatment with PEG-IFN/
RBV therapy were reported to be associated with decreased several 
blood cells, such as; white blood cells (neutropenia), red blood cells 
(anemia), and platelets (thrombocytopenia), which can delay or 
prevent treatment [10]. We suggested, in our previous study, that 
pretreatment neutrophil count and the degree of decline can be 
useful in predicting how HCV genotype 4 patients would respond 
to therapy. We also postulated that neutropenia during PEG-IFN 
therapy, could reflect viral clearance of infected neutrophil rather 
than being an adverse effect [11]. Other studies reported that, 
HCV is directly involved in the process that, at least in part, leads 
to thrombocytopenia [12]. 
Detection of HCV has been reported in extrahepatic sites such 
as peripheral blood mononuclear cells and platelets, the quantitation 
of HCV-RNA in platelets or leucocyte components from patients 
under antiviral therapy is rarely studied and generated contradictory 
results. Since the complex function of platelets’ HCV-RNA and 
platelets count in predicting response to therapy has not been well 
characterized, we decided to explore the possible interplay between 
response to treatment with platelets count and platelets’ HCV-RNA 
viral load in 20 chronically HCV-G4 infected patients. Therefore, we 
examined and quantified the presence of HCV-RNA in platelet. In 
addition, we evaluated the relation between HCV-RNA in the serum 
and the kinetics of HCV-RNA in platelet in response to treatment.
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examine predictors of SVR and viral loads accounting for repeated 
measurements on the same individual and covariates. Subsequently, 
we examined whether platelet count, or platelets viral load is superior 
to serum viral load in predicting SVR using ROC curve method. SAS 
9.32 (SAS Inc., Cary, North Carolina, USA) was used for all analyses.
Results
The study included 20 HCV-G4 patients who received PEG-IFN/
RBV therapy. Most of the study participants were men (95%), with a 
baseline median (interquartile range) age 46 (38.5,50.5) years, platelet 
counts 166 (150.5,222), log10 serum viral load 7.56 (6.43,8.10) and 
log10 platelet viral load 3.52 (0.0,5.09). RVR, EVR, ETR, and SVR were 
observed in 35%, 70%, 75% and 55% respectively. Approximately 27% 
of those who had ETR, relapsed at 72 weeks, with an overall relapse 
rate of 20%, and nonresponse of 25%.In the bivariate unadjusted 
analysis, only baseline platelet viral load was significantly different 
between those who had SVR and non-responders, while there were 
no age, serum viral load, platelet count, spleen size, inflammation or 
fibrosis significant differences (Table 1).
While, patients experiencing RVR had sharp reductions in serum 
viral load by week 4 of ~zero, which remained around zero levels 
through week 48, which is followed by a slight increase at week 72 
in some individuals (Figure 1). In contrast, non-responders had a 
slower decline in serum viral loads to reach the lowest values at 48 
weeks and then showed an increase by 72 weeks. On the other hand, 
platelet viral load among RVR showed a sharp decline by week 4 but 
did not reach zero levels, and remained almost constant afterward. 
Individuals with non-RVR had a steeper decline in platelet viral load 
until week 12, which was followed by an increase by week 48. Platelet 
count tended to be lower among those with RVR compared to those 
with non-RVR throughout the follow up. Of note, among individuals 
with RVR platelet counts declined slightly by week 4 and week 12 
then gradually increased to reach pre-treatment levels by week 48, 
but there was no similar decline among patients who did not achieve 
RVR (Figure 2).
As illustrated in Figure 1, patients with EVR experienced sharp 
reduction of serum viral load to reach ~zero by week 12 and week 
48, which was followed by an increase by week 72. EVR group also 
demonstrated a drop in platelet viral load by week 4, which remained 
almost constant through the remaining follow up (Figure 2). In 
addition, patients with EVR had a decline in platelet count to reach 
the lowest level at week 12 followed by an increase in platelet count 
by week 48 (Figure 3). In contrast to patients with EVR, patients who 
did not achieve EVR had a very slow reduction in serum viral load 
to reach the lowest values by 48 weeks which was followed by an 
increase (Figure 1). We also observed no change in platelets’ viral load 
by week 4, followed by reaching its lowest levels at week 12 which was 
followed by an excess by week 48 (Figure 2). Interestingly individuals 
with no-EVR had a progressive increase in platelet count to reach the 
highest level at week 12, and then were followed by decline (Figure 3).
By week 4, platelets’ viral load showed sharp declines among SVR 
to reach approximately zero and remains ~0 throughout the follow 
up. On the other hand, among non-SVR, the platelets’ viral load 
decline continues until the 12th week, and then an increase in the 
platelets’ viral load is observed throughout the remaining period of 
follow up (Figure 2). In comparison, the observed decline in serum 
viral load (Figure 1) is steeper than the decline in platelet viral load 
(Figure 2), such that both SVR and non-SVR show steep decline in 
serum viral load until the 12th week where the responders viral load 
Materials and Methods
Sample population 
Twenty chronic HCV genotype 4 patients who were scheduled to 
receive treatment at the Hepatology clinic at Hamad General Hospital 
(HGH) were selected. The prescribed treatment consisted of PEG-
IFN and RBV according to body weight. Patients were considered to 
have chronic HCV infection if they had sustained increase in alanine 
aminotransferase (ALT), positive anti-HCV serology, detectable 
HCV-RNA, and histopathological evidence of chronic active 
hepatitis. Patients were excluded from the study if they had any other 
disease or receiving treatment which may affect platelet count. The 
treatment regimen was 48-week a once weekly subcutaneos, 180 μg of 
Peginterferon-2a (Pegasys®, Hoffmann-La Roche, Basel, Switzerland) 
and 1000 mg (body weight ≤ 75 kg) or 1200 mg (body weight ≥ 75 
mg) of oral Ribavirin (COPEGUS®; Hoffmann-La Roche). We defined 
end of treatment response (ETR) and sustained viral response (SVR) 
as undetectable serum HCV RNA at the end of treatment (48 week) 
and at the end of follow up (72 week) respectively.The study started 
after obtaining the approval of the ethics research committee of the 
Hamad Medical Corporation. All patients provided written informed 
consent the study was funded by UREP grant 09-065-3-010, QNRF.
Sample collection 
A total of 14 mL blood was collected at each time point. More 
specifically, 10 mL whole blood samples were collected and added to 
3.2% ACD vacutainer tubes; and additional 4 mL blood samples were 
collected without anticoagulant agent for serum preparation. Blood 
samples were collected at the following time points: pre‐treatment, 
4, 12, and 48 weeks post‐treatment. To detect sustained virological 
response to treatment, serum samples were also collected on week 72.
Sample laboratory analysis
Platelet rich plasma was prepared by centrifuging citrated whole 
blood sample at 150xg for 10min. The plasma was transferred to 
another plain tube and then re-centrifuged at 150xg for 10min to 
obtain a platelet pellet. The pellet was washed seven times with 
Tyrode’s solution, which helped to maintain a healthy platelet 
population and prevented further cell disruption. HCV‐RNA 
extraction was completed promptly using the QIAamp Viral RNA 
and RNeasy Mini kit (QIAGEN, Hilden, Germany) according to 
manufacturer’s instructions. Briefly, samples were homogenized and 
cells were lysed using the RLT buffer supplied with the kit. To each 
sample 70% ethanol was applied to enhance clean up. Each sample 
was then passed through a specialized column that binds the total 
RNA. Before elution, the samples were cleaned up from any residual 
DNA by applying DNAse, and then the sample was eluted and 
collected by spinning at × 10,000 RPM using a table top centrifuge. 
The final concentration of the extracted RNA was measured using 
spectrophotometry.
Statistical analysis 
Individuals were classified as having rapid viral response (RVR), 
early viral response (EVR), end of treatment response (ETR), and 
sustained viral response (SVR) if they had undetectable HCV-RNA 
at weeks 4, 12, 48, and 72 respectively. Bivariate associations were 
tested using t-tests and chi-square tests. In addition, we examined 
Spearman correlations between various variables. To adjust for 
covariates, multivariable regression models were employed using 
generalized estimating equation (GEE) models, and mixed models to 
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become very close to zero, whereas afterwards non-SVR viral load 
remains high but steady until the 48th week, then it increase again 
(Figure 1). Platelet count remained almost constant over time, among 
non-SVR, but among SVR it should steady small decline until week 
12, then it started to increase to pre-treatment levels (Figure 3).
As shown in Table 2, platelet viral load at week 4 significantly 
positively correlated with platelet viral loads, and serum viral loads 
at successive time points, but significantly negatively correlated with 
EVR, and SVR. Platelet viral load at week 12 significantly positively 
correlated with platelet viral load at week 48, and serum viral load at 
week 72, but significantly negatively correlated with SVR. Similarly, 
platelet viral load at the 48th week was significantly correlated with 
serum viral loads at the 48th and 72nd weeks and negatively correlated 
with SVR. Serum viral load at 12th weeks significantly correlated with 
viral loads at the 4th, 48th, and 72nd weeks and negatively correlated 
with RVR, EVR, and SVR. Serum viral load at week 48 significantly 
correlated with serum viral load at the 72nd week, as well as negatively 
correlated with RVR, EVR and SVR. Platelets count at any time point 
positively significantly correlated with platelet count at any other 
time point, but did not correlate with platelet or serum viral loads or 
treatment responses (Table 2).
A more detailed examination of the relapsed cases, revealed that 
all those patients had a one or more visit where serum viral load was 
undetectable, but the platelet viral load was still detectable (Table 3). 
We further examined whether the serum viral load, platelet viral load 
and platelet count values measured over time predicted SVR or not. 
All  
N=20
No SVR 
N=9
SVR 
N=11 P value
Age median (IQR) 46(38.5,50.5)
46
(44,50)
46
(35,53) 0.91
Baseline serum log10 viral load median (IQR) 7.56(6.43,8.10)
7.67
(6.63,8.06) 7.52 (6.42,8.14) 0.76
Baseline platelet viral load median (IQR) 3.52(0.0,5.09)
4.44
(3.86,5.14) 0.00 (0.00,4.90) 0.04
Baseline platelet count median (IQR) 166(150.5,222)
162
(150-215) 169 (151,250) 0.87
Spleen size median (IQR) 11.35(9.60,14.15)
13.0
(11.1,15.0) 11.1 (9.6,13.2) 0.31
Inflammation N (%)
I & II 14 (77.78%) 5 (35.7%) 9 (64.3%) 0.61
III & IV 4 (22.22%) 2 (50.0%) 2 (50.0%)
Fibrosis N (%)
I & II 10 (55.56%) 2 (20.0%) 8 (80.0%) 0.07
III & IV 5 (44.44%) 5 (62.5%) 3 (37.5%)
Table 1: Selected pretreatment characteristics by SVR status.
Log serum viral load by week 
and RVR status
Log serum viral load by week 
and EVR status
Log serum viral load by week 
and SVR status
WEEK 0           WEEK 4         WEEK 12        WEEK 48        WEEK 72 WEEK 0           WEEK 4          WEEK 12        WEEK 48        WEEK 72 WEEK 0           WEEK 4          WEEK 12        WEEK 48        WEEK 72
RVR            NO RVR EVR            NO EVR SVR             NO SVR
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 Figure 1: Mean serum log viral load over time by response status.
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Log platelets’ viral load by 
week and RVR
Log platelets’ viral load by 
week and EVR
Log platelet viral load by week and
SVR
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WEEK 0                 WEEK 4               WEEK 12              WEEK 48WEEK 0                 WEEK 4                WEEK 12              WEEK 48 WEEK 0                    WEEK 4                   WEEK 12                  WEEK 48
SVR            NO SVREVR              NO EVRRVR              NO RVR
Figure 2: Mean platelet log viral load over time by the response status.
Citation: Amer A, Madi MA, Shebl FM, Faridi DA, Alkhinji M, et al. (2016) Platelet as a Possible Reservoir of HCV And Predictor of Response to Treatment. 
J Virol Antivir Res 5:3.
• Page 4 of 7 •
doi: 10.4172/2324-8955.1000157
Volume 5 • Issue 3 • 1000157
Serum viral load, significantly predicted SVR, such that for each unit 
increase in log serum viral load, the odds of SVR decreased by 27% 
(OR 0.73 95% CI 0.64, 0.83, P<.0001). Similarly, platelet viral load 
predicted SVR such that for each unit decrease in log platelet viral 
load, the odds of SVR increase by ~2.13 times (P<.0001). Platelet 
count over time did not significantly predict SVR (Table 4).
Mixed models were run to examine predictors of serum and 
platelet viral load accounting for the time of sample collection. The 
serum viral load was positively associated with platelet viral load 
(t=3.58, p=0.001), and platelet count (t=6.79, p=0.02). The Platelet 
viral load was related to serum viral load (t=3.39, p=0.001), but not 
related to platelet count (t=-0.56, p=0.58), or weak levels (t=0.64, 
p=0.52). Platelet count was significantly positively associated with 
log serum viral load (t=10.25, p=0.002), but not with log platelet viral 
load (t=-0.97, p=0.33), or week (t=1.27, p=0.21).
ROC curve analysis revealed that in general platelet viral load 
at different time points were better predictors of SVR compared to 
serum viral load. More specifically, platelet viral loads at baseline, 
week 4, week 12, and week 48 had AUC of 81%, 93%, 79%, and 100% 
respectively. In contrast, serum viral loads at baseline, week 4, week 
12, and week 48 had AUC of 58%, 71%, 69%, and 71% respectively. 
Since serum viral load is usually used to predict SVR, we compared 
ROC curves of each of the indicators to ROC curve of serum viral 
load at baseline. The ROC curve of platelet viral load at week 4 and 
week 48 were significantly better than ROC curve of serum viral load 
at baseline, therefore, platelet viral loads are better clinical predictors 
of response to treatment (Table 5).
Discussion
Detection of HCV-RNA in different in mononuclear 
subpopulation and platelet, has been documented in a few studies, 
which was hampered by small size samples [12]. Similar to de Almeida 
[13], all our patients harbor HCV-RNA in their platelets before and 
throughout the course of therapy, independent of pre-treatment viral 
load or platelet counts. As shown in our study, HCV-RNA levels 
were higher in serum than in platelets, regardless of time of antiviral 
therapy, which was in agreement with previous studies [14]. This 
confirms that platelets may serve as reservoirs of HCV and protect 
virions from immune recognition. Whether, this immune escape will 
play a role in developing viral mutations in HCV with resistance to 
the recently approved protease and non-nucleoside inhibitors.
This reported detection of HCV-RNA in peripheral blood 
components; raise the question about the correlation between 
response and/or relapse with the detectable viral genome in the 
platelet. Despite HCV-RNA elimination from blood serum during 
treatment in some patients, HCV viremia appears again after the 
completion of therapy. Despite hepatocytes being the primary target 
cells of HCV, however, HCV-RNA has been detected in other cells, 
such as platelets, which have been described as carriers of the virus in 
the circulation of infected patients. Some studies have suggested that 
PBMC could serve as a reservoir for virus resistant to IFN therapy, 
therefore, could be one of the mediating mechanisms of relapse [15]. 
In the current study, we found that patients with undetectable serum 
HCV-RNA but have detectable HCV-RNA in their platelets after 
completion of anti-viral therapy, would be at greater risk of HCV 
relapse compared to those without HCV-RNA in their platelets. We 
also found that, those who relapsed had detectable HCV-RNA in their 
platelets in spite of being negative in peripheral blood. Platelets do not 
express CD81 or the classical LDL-R, suggesting that other receptors/
molecules are involved in the entry of HCV-RNA to the platelets 
[16]. HCV interaction with the platelet membrane glycoprotein VI, 
might explain the viral binding to platelets in infected patients [17]. 
According to our findings, any effective treatment should be effective 
in clearance if infected platelets, as platelets act as reservoirs for the 
virus and HCV is known to replicate in megakaryocytes
Although the majority of sustained responders eventually loses 
HCV RNA from PBMCs [18], it should be noted that patients with 
detectable HCV-RNA in platelets or PBMCs represents a potential source 
of HCV spread, even if they were HCV-RNA serum negative. While 
including the RBC fraction of the tested sample was reported not to increase 
assay sensitivity [19], our data indicated that a significant proportion of 
HCV RNA in peripheral blood is not identified by standard plasma RNA 
detection methods. Thus measuring HCV-RNA in serum or plasma may 
underestimate the true HCV burden. The importance of the early detection 
of relapse is of paramount importance in PEG-IFN based therapy, as well as 
with the more expensive IFN-free direct acting therapy, when considering a 
prolonged course of 24 weeks or to shift to a mixture of antiviral drugs.
Conclusion 
Our data reconfirm higher HCV-RNA levels in serum compared 
to platelet, independent of time point of antiviral therapy. We suggest 
that, the HCV RNA analysis in plasma, may underestimate circulating 
virus load. Thrombocytopenia occurring during interferon-based 
therapy might be manifestation of viral eradication rather than 
adverse effects. Our findings warrant testing the sensitivity of platelet 
viral load as a predictor of poor response in a larger sample size, and 
that early eradication of HCV-RNA from platelet, is associated with 
higher rates of SVR.
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Patient 3 5.04 6.63 5.06 5.40 4.30 0.00 5.06 0.00 8.39
Patient 4 5.83 8.78 5.92 7.84 0.00 4.66 3.19 0.00 7.57
Table 3: Platelet and serum viral load among relapsers.
OR* OR 95% CI Chi-square P value
Serum viral load 0.73 0.64 0.83 24.77 <.0001
Platelet viral load 0.47 0.35 0.63 25.5 <.0001
Platelet count 1 0.99 1.01 0.2 0.652
*Interpreted as the change in the odds of SVR for each unit increase of continuous predictors.
Table 4: The association between serum viral load, platelet viral load and platelet count overtime and SVR.
 AUC AUC 95% CI Contrast Chi-square P value  
Platelet VL W0 0.8052 0.5945 1 0.2208 1.4431 0.2296
Platelet VL W4 0.9286 0.7886 1 0.3442 7.8919 0.005
Platelet VL W12 0.7857 0.5877 0.9837 0.2013 1.1392 0.2858
Platelet VL W48 1 1 1 0.4156 7.9751 0.0047
Serum VL W0 0.5844 0.296 0.8728 ref ref ref
Serum VL W4 0.7143 0.4601 0.9685 0.1299 0.4703 0.4928
Serum VL W12 0.6883 0.4664 0.9102 0.1039 0.4611 0.4971
Serum VL W48 0.7143 0.5163 0.9123 0.1299 0.371 0.5425
Table 5: Area under the curve of different possible predictors of SVR.
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